Cardiac myosin
Cardiac myosin-Th17 responses promote heart failure in human myocarditis
20
Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice
7
Distribution of cardiac myosin isozymes in human conduction system Immunohistochemical study using monoclonal antibodies
9
Increase in cardiac myosin heavy chain (MyHC) alpha protein isoform in hibernating ground squirrels, with echocardiographic visualization of ventricular wall hypertrophy and prolonged contraction
13
HSC70 is a chaperone for wild-type and mutant cardiac myosin binding protein C
17
Autoimmunity in Chagas' disease Identification of cardiac myosin B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient
5
Cardiomyopathy mutations in the tail of beta cardiac myosin modify the coiled-coil structure and affect integration into thick filaments in muscle sarcomeres in adult cardiomyocytes.
23
Research Progress of Cardiac Myosin Binding Protein C in Dilated Cardiomyopathy and Other Cardiac Conditions
10
Localization of cardiac myosin specific antibody in myocardial infarction
9
Novel splice donor site mutation in the cardiac myosin binding protein C gene in familial hypertrophic cardiomyopathy Characterization Of cardiac transcript and protein
9
A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart
14
The protective effect of Er Xian decoction against myocardial injury in menopausal rat model
10
Curcumin ameliorates experimental autoimmune acute myocarditis in rats as evidenced by decrease in thioredoxin immunoreactivity
7
Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications to Autoimmune Disorders and Organ Transplantation
11
Mouse and computational models link Mlc2v dephosphorylation to altered myosin kinetics in early cardiac disease
14
Functional analysis of the mutations in the human cardiac beta myosin that are responsible for familial hypertrophic cardiomyopathy Implication for the clinical outcome
9
Diabetes with heart failure increases methylglyoxal modifications in the sarcomere, which inhibit function
18
Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program
9
Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations
7
Cardiac beta myosin heavy chain diversity in normal and chronically hypertensive baboons
8